Kaurenoic acid (Synonyms: 異貝殼杉烯酸；貝殼杉烯酸)

目錄號(hào): HY-N1469 純度: 99.56%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Kaurenoic acid 是一種來(lái)源 Sphagneticola trilobata 的二萜。Kaurenoic acid 具有抗菌，抗炎，抗驚厥，鎮(zhèn)痛，主動(dòng)脈血管松弛作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Kaurenoic acid Chemical Structure

CAS No. : 6730-83-2

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥499	In-stock
1 mg	￥300	In-stock
5 mg	￥750	In-stock
10 mg	￥1200	In-stock
25 mg	￥2238	In-stock
50 mg	￥3338	In-stock
100 mg	￥4863	In-stock
200 mg		詢價(jià)
500 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Kaurenoic acid:

Kaurenoic acid (Standard) 詢價(jià)

Kaurenoic acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Kaurenoic acid is a diterpene derived from Sphagneticola trilobata. Kaurenoic acid has antibacterial, anti-inflammatory, anticonvulsant, analgesic, and aortic vasodilating effects^[1]^[2]^[3]^[4].

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A498	ED₅₀	47.97 μg/mL Compound: 2	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8882434]
A549	ED₅₀	13.59 μg/mL Compound: 2	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882434]
B16-F10	IC₅₀	54.79 μM Compound: 6	Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HaCaT	CC₅₀	108.6 μM Compound: 1	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]
HEK293	IC₅₀	357 nM Compound: 1b	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HeLa	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HepG2	CC₅₀	192.4 μM Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23353738]
HepG2	IC₅₀	50.72 μM Compound: 6	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HL-60	IC₅₀	44.11 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HT-29	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HT-29	ED₅₀	31.39 μg/mL Compound: 2	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8882434]
K562	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human K562 cells after 72 hrs by inverted microscopy Growth inhibition against human K562 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
K562	IC₅₀	72.53 μM Compound: 6	Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
LLC-MK2	IC₅₀	16.5 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method	[PMID: 22440015]
LLC-MK2	EC₅₀	596 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method	[PMID: 22440015]
LLC-MK2	CC₅₀	76.1 μM Compound: 7	Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay	[PMID: 22440015]
LoVo	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy	[PMID: 23353738]
MCF7	ED₅₀	1 μg/mL Compound: 2	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8882434]
MIA PaCa-2	ED₅₀	22.13 μg/mL Compound: 2	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8882434]
PANC-1	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
PBMC	IC₅₀	0.002 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	0.01 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	7.7 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	80.77 μM Compound: 6	Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay	[PMID: 24969014]
PC-3	ED₅₀	15.19 μg/mL Compound: 2	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8882434]
RAW264.7	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 20116261]
RAW264.7	IC₅₀	> 25 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 21334121]
SH-SY5Y	CC₅₀	45.4 μM Compound: 1	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]

體外研究
(In Vitro)

Kaurenoic acid (10-100 μM，60 min) 濃度依賴性地抑制腎上腺素和 KCl 誘導(dǎo)的內(nèi)皮完整或剝離大鼠主動(dòng)脈環(huán)收縮^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Kaurenoic acid (1-10 mg/kg，灌胃，單次劑量) 減輕小鼠脂多糖 (HY-D1056) 誘導(dǎo)的腹膜炎和疼痛^[2]。
Kaurenoic acid 作為二萜類化合物，在 A. senegalensis 根皮提取物中是小鼠抗驚厥作用的主要活性成分^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice induced by LPS^[2]
Dosage:	1, 3, 10 mg/kg; single dose
Administration:	i.g.
Result:	Inhibited LPS-induced mechanical and thermal hyperalgesia, suppressed MPO activity, regulated the redox state of mouse paws, inhibited the production of pro-inflammatory/pain cytokines (such as TNF-α, IL-1β, and IL-33), and enhanced the production of anti-inflammatory/analgesic cytokine IL-10.

分子量

302.45

Formula

C₂₀H₃₀O₂

CAS 號(hào)

6730-83-2

性狀

固體

顏色

White to off-white

中文名稱

異貝殼杉烯酸；貝殼杉烯酸

結(jié)構(gòu)分類

初始來(lái)源

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 100 mg/mL (330.63 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.3063 mL	16.5317 mL	33.0633 mL
5 mM	0.6613 mL	3.3063 mL	6.6127 mL
10 mM	0.3306 mL	1.6532 mL	3.3063 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.56%

選擇批次：

Data Sheet (636 KB) SDS (393 KB)

COA (294 KB) HNMR (288 KB) LCMS (258 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Carlos R Tirapelli, et al. Analysis of the mechanisms underlying the vasorelaxant action of kaurenoic acid in the isolated rat aorta. Eur J Pharmacol. 2004 May 25;492(2-3):233-41. [Content Brief]

[2]. Sergio M Borghi, et al. The diterpene from Sphagneticola trilobata (L.) Pruski, kaurenoic acid, reduces lipopolysaccharide-induced peritonitis and pain in mice. J Ethnopharmacol. 2021 Jun 12:273:113980. [Content Brief]

[3]. Theophine C Okoye, et al. Anticonvulsant effect of kaurenoic acid isolated from the root bark of Annona senegalensis. Pharmacol Biochem Behav. 2013 Aug:109:38-43. [Content Brief]

[4]. Mizokami SS, et al. Kaurenoic acid from Sphagneticola trilobata Inhibits Inflammatory Pain: effect on cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway. J Nat Prod. 2012 May 25;75(5):896-904. [Content Brief]

Kaurenoic acid 相關(guān)分類

Neurological Disease Inflammation/Immunology Infection

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3063 mL	16.5317 mL	33.0633 mL	82.6583 mL
	5 mM	0.6613 mL	3.3063 mL	6.6127 mL	16.5317 mL
	10 mM	0.3306 mL	1.6532 mL	3.3063 mL	8.2658 mL
	15 mM	0.2204 mL	1.1021 mL	2.2042 mL	5.5106 mL
	20 mM	0.1653 mL	0.8266 mL	1.6532 mL	4.1329 mL
	25 mM	0.1323 mL	0.6613 mL	1.3225 mL	3.3063 mL
	30 mM	0.1102 mL	0.5511 mL	1.1021 mL	2.7553 mL
	40 mM	0.0827 mL	0.4133 mL	0.8266 mL	2.0665 mL
	50 mM	0.0661 mL	0.3306 mL	0.6613 mL	1.6532 mL
	60 mM	0.0551 mL	0.2755 mL	0.5511 mL	1.3776 mL
	80 mM	0.0413 mL	0.2066 mL	0.4133 mL	1.0332 mL
	100 mM	0.0331 mL	0.1653 mL	0.3306 mL	0.8266 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kaurenoic acid6730-83-2異貝殼杉烯酸貝殼杉烯酸Potassium ChannelBacterialKcsAAntibacterialanti-inflammatoryanticonvulsantanalgesicaortic vasorelaxantInhibitorinhibitorinhibit

您最近查看的產(chǎn)品:

產(chǎn)品名稱：

* 需求量：

* 客戶姓名：

* Email：

* 電話：

* 公司或機(jī)構(gòu)名稱：

留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。

站點(diǎn)地圖隱私聲明

滬ICP備15051369號(hào)-4

上海工商

滬公網(wǎng)安備31011502019417

滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS)

營(yíng)業(yè)執(zhí)照（三證合一）

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Kaurenoic acid (Synonyms: 異貝殼杉烯酸；貝殼杉烯酸)

Customer Review

Other Forms of Kaurenoic acid: